Shared on08 Oct 25Fair value Increased 5.45%
Arcus Biosciences’ analyst price target has been raised from $28.36 to $29.91 per share, as analysts cite promising updated trial results for Casdatifan. These results are supporting an increased company valuation.
Shared on17 Apr 25Fair value Decreased 2.54%
AnalystConsensusTarget has increased revenue growth from -0.7% to -0.4% and decreased profit margin from 19.3% to 17.3%.
Shared on09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Decreased 45%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.